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Letters
spondyloarthropathies, they are separate enti-
ties. Both are distinct from rheumatoid arthritis.
Darren R. Blumberg and Victor S. Sloan
Robert Wood Johnson Medical School, New
Brunswick, New Jersey, USA
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Reply to Drs. Blumberg and Sloan
To the Editor: I concur with your comments. After
reviewing the literature related to foodborne
disease, it appears that the original classification
of reactive arthritides has been in error for some
time. I certainly appreciate the correction.
James A. Lindsay
University of Florida, Gainesville, Florida, USA
Cost of Blood Screening
To the Editor: In reference to G.A. Schmunis’
article on the risk for transfusion-transmitted
infections in Central and South America (1), I
would like to comment on the cost of blood
screening. In a screening program, the objective
is to have safe blood units, not to assess the
prevalence of different infections among poten-
tial or actual donors. Thus, while acknowledging
all infections present in a given donor or potential
donor is not required, detecting at least one of the
infections that would make a donor noneligible is. If
samples from every potential donor are subjected
(by default) to all the tests, information on every
infection present is provided, and the cost of
screening this donor is the sum of the cost of every
test applied; in this case, both the information and
the cost are greater than necessary.
Information on the prevalence of bloodborne
infections among the general population or,
preferably, among potential donors (particularly
where professional donors are frequent) along
with information on the costs of the tests to be
used can form the basis of a stepwise screening
scheme. Tests for infections with the highest
prevalence would be applied first. For example,
in many areas of Peru, using the Venereal
Disease Research Laboratory (VDRL) test (for
screening Treponema pallidum infection) first
would reduce the number of samples to be
subjected to other more expensive and often less
available tests (e.g., HIV enzyme-linked
immunosorbent assay [ELISA] or hepatitis C
virus [HCV] ELISA); in others areas, a test for
hepatitis B virus antigen (HBsAg) should be used
before HIV ELISA. The reduction in cost
provided by stepwise screening will depend on
the prevalences of the more frequent infections
and the frequency of concurrent infections.
The questionnaires applied to candidate
donors should be validated, and the benefit of
using them should be assessed. In most settings,
candidate donors are either ignorant of their
status as carriers of bloodborne infection or ready
to deny it; therefore, the questionnaire is of little
use. In some cases candidate donors are turned
down because of “hepatitis history” when in fact
they have not had bloodborne hepatitis.
Finally, screening tests seem to be quite more
expensive than reported in Table 4 of the Schmunis
article. In Lima, at a ministry of health facility,
some prices are as follows: HIV ELISA US$12.50,
VDRL US$6.40, HBsAg US$13.90.
O. Jaime Chang
Instituto Nacional de Salud, Ministerio de Salud,
Lima, Peru
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